Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06857006 · ClinicalTrials.gov registry record · NA
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
A NA study of Brain Metastases, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 180
- Enrollment target
- 1
- Study location
NCT06857006: Recruiting NA study of Brain Metastases, sponsored by University of Alabama at Birmingham.
NCT06857006 is a NA study of Brain Metastases that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 180 participants, below the 210-participant average among 67 other Brain Metastases trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06857006, a NA study of Brain Metastases, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 180 participants
- Enrollment target
- 1
- Study location
Study Summary
Radiosurgery is the use of a focal high dose of radiation therapy to ablate or kill a tumor. This trial will enroll patients with brain metastases 4 cm or less in greatest diameter and will compare 0mm margin to a 2mm margin for treatment.
Primary Outcome
Fisher's Exact Test to determine if (per patient) uncomplicated control is improved or worsened with the addition of a 2mm PTV margin in the treatment of brain metastases with single isocenter radiosurgery.
Conditions Studied
Interventions
- PROCEDURE brain metastases radiosurgery
Study Locations (1)
Alabama
- University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-04-08 |
| Est. Completion | 2028-08 |
| Phase | NA |
What NCT06857006 shows while recruiting
NCT06857006 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, below the 210-participant average among 67 other Brain Metastases trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which brain metastases radiosurgery is the first listed.
NCT06857006 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT06857006 about?
NCT06857006 is a clinical study titled "Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases". Radiosurgery is the use of a focal high dose of radiation therapy to ablate or kill a tumor. This trial will enroll patients with brain metastases 4 cm or less in greatest diameter and will compare 0mm margin to a 2mm margin for treatment.
What is the current status of trial NCT06857006?
This trial is currently recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2025-04-08. Estimated completion is 2028-08.
What conditions does trial NCT06857006 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT06857006?
The interventions under investigation include: brain metastases radiosurgery (PROCEDURE).
Who is sponsoring clinical trial NCT06857006?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06857006 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06857006's enrollment target sits among peer trials
180 7th of 67 higher than 61 of 67 other Brain Metastases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
RECRUITING · NA
-
REMASTer: REcurrent Brain Metastases After SRS Trial
RECRUITING · NA
-
Development of MRF for Characterization of Brain Tumors After Radiotherapy
RECRUITING · NA
-
MeDex: No Perioperative Dexamethasone in Brain Metastases
RECRUITING · NA
-
A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI